Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Rising Dose Study of TAK-925 in Healthy Volunteers and Patients with Narcolepsy
jRCT2080224146Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) (7 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of multiple rising intravenous doses of TAK-925, Safety and tolerability of single oral doses of TAK-925 and 2 more. Started Nov 2018; status: completed.
02
Drugs
danavorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on jRCT2080224146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224146.